Human Testing Without Human Subjects – A Pathway to More Effective, Rapid, and Less Expensive Drug Development
INTERVIEW ON THE PRICE OF BUSINESS SHOW, MEDIA PARTNER OF THIS SITE.
Recently Kevin Price, Host of the nationally syndicated Price of Business Show, interviewed Frank H. Lau, MD, CEO, Founder, Keliomics, Inc..
Keliomics is an oncology biotech startup whose revolutionary ex vivo tumors (EVTs) help biopharmaceutical companies select the best new therapeutics to advance into clinical trials. These EVTs leapfrog current technologies by growing tumors in donated human tissues, such as breast cancer in human breast tissue. This disruptive technology enables, for the first time, human data before human testing.
Keliomics sources the donor tissues, produces the EVTs, and tests biopharmaceuticals based on a myriad of possible customer specifications. This approach allows Keliomics to generate real-world human data before having to recruit patients into human clinical trials, which are slow and expensive.
To date, Keliomics has developed EVTs for breast cancer, colon cancer, and melanoma. These tumors preserve key factors that govern patients’ response to therapy, including obesity status, menopausal status, and immune status. Funding from their open seed round is being used to clinically benchmark their tumors to gold standard clinical trial data. These efforts will definitively validate Keliomics’ lab-curated tumors as predictor of real-world patient results, allowing human drug testing before going into clinical trials.
Importantly, Keliomics’ technology allows thousands of tumors to be produced from each donor’s tissue. For the first time, this technology delivers readouts of complex, human tumor-drug-microenvironment interactions. These novel, large, human-quality datasets can be used for AI training.
To-date, Keliomics has used its platform to accelerate the development of cancer drugs including monoclonal antibodies for many types of tumors. The company is being led by scientists and biopharmaceutical veterans from leading universities and drug development companies. For more information, visit www.kelioimcs.com.
For more great lifestyle content see here.
LISTEN TO THE INTERVIEW IN ITS ENTIRETY HERE:
The Price of Business is one of the longest running shows of its kind in the country and is in markets coast to coast. The Host, Kevin Price, is a multi-award winning author, broadcast journalist, and syndicated columnist. Learn more about the show and its digital partners at www.PriceofBusiness.com (scroll down to the bottom of the page).
